Feb 6 (Reuters) - Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines ...
Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...
VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
Sanofi said a U.S. regulatory decision on its tolebrutinib experimental treatment for a type of multiple sclerosis would be delayed again, and that a late-stage trial for a different form of the ...
FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its ...
Researchers at the University of Arizona College of Medicine—Tucson found evidence that a drug that improves the ability to walk in people with multiple sclerosis can also make bone fractures heal ...
BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results